ChloroquineV1, Ncbi, Merge, bibRecord, 000463

Metastatic cells are preferentially vulnerable to lysosomal inhibition.

Identifieur interne : 000463 ( Ncbi/Merge ); précédent : 000462; suivant : 000464

Metastatic cells are preferentially vulnerable to lysosomal inhibition.

Auteurs : Michael J. Morgan [États-Unis] ; Brent E. Fitzwalter [États-Unis] ; Charles R. Owens [États-Unis] ; Rani K. Powers [États-Unis] ; Joseph L. Sottnik [États-Unis] ; Graciela Gamez [États-Unis] ; James C. Costello [États-Unis] ; Dan Theodorescu [États-Unis] ; Andrew Thorburn [États-Unis]

Source :

Proceedings of the National Academy of Sciences of the United States of America [ 1091-6490 ] ; 2018.

RBID : pubmed:30127018

Descripteurs français

KwdFr :
- Animaux, Chloroquine (pharmacologie), Humains, Lignée cellulaire tumorale, Lysosomes (anatomopathologie), Lysosomes (métabolisme), Macrolides (pharmacologie), Métastase tumorale, Protéines d'inhibition de la différenciation (biosynthèse), Protéines tumorales (biosynthèse), Régulation de l'expression des gènes tumoraux (), Résistance aux médicaments antinéoplasiques (), Souris, Tumeurs de la vessie urinaire (anatomopathologie), Tumeurs de la vessie urinaire (génétique), Tumeurs de la vessie urinaire (métabolisme), Tumeurs de la vessie urinaire (traitement médicamenteux), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (métabolisme), Tumeurs du poumon (secondaire), Tumeurs du poumon (traitement médicamenteux).
MESH :
- anatomopathologie : Lysosomes, Tumeurs de la vessie urinaire, Tumeurs du poumon.
- biosynthèse : Protéines d'inhibition de la différenciation, Protéines tumorales.
- génétique : Tumeurs de la vessie urinaire.
- métabolisme : Lysosomes, Tumeurs de la vessie urinaire, Tumeurs du poumon.
- pharmacologie : Chloroquine, Macrolides.
- secondaire : Tumeurs du poumon.
- traitement médicamenteux : Tumeurs de la vessie urinaire, Tumeurs du poumon.
- Animaux, Humains, Lignée cellulaire tumorale, Métastase tumorale, Régulation de l'expression des gènes tumoraux, Résistance aux médicaments antinéoplasiques, Souris.

English descriptors

KwdEn :
- Animals, Cell Line, Tumor, Chloroquine (pharmacology), Drug Resistance, Neoplasm (drug effects), Gene Expression Regulation, Neoplastic (drug effects), Humans, Inhibitor of Differentiation Proteins (biosynthesis), Lung Neoplasms (drug therapy), Lung Neoplasms (metabolism), Lung Neoplasms (pathology), Lung Neoplasms (secondary), Lysosomes (metabolism), Lysosomes (pathology), Macrolides (pharmacology), Mice, Neoplasm Metastasis, Neoplasm Proteins (biosynthesis), Urinary Bladder Neoplasms (drug therapy), Urinary Bladder Neoplasms (genetics), Urinary Bladder Neoplasms (metabolism), Urinary Bladder Neoplasms (pathology).
MESH :
- chemical , biosynthesis : Inhibitor of Differentiation Proteins, Neoplasm Proteins.
- chemical , pharmacology : Chloroquine, Macrolides.
- drug effects : Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic.
- drug therapy : Lung Neoplasms, Urinary Bladder Neoplasms.
- genetics : Urinary Bladder Neoplasms.
- metabolism : Lung Neoplasms, Lysosomes, Urinary Bladder Neoplasms.
- pathology : Lung Neoplasms, Lysosomes, Urinary Bladder Neoplasms.
- secondary : Lung Neoplasms.
- Animals, Cell Line, Tumor, Humans, Mice, Neoplasm Metastasis.

Abstract

Molecular alterations that confer phenotypic advantages to tumors can also expose specific therapeutic vulnerabilities. To search for potential treatments that would selectively affect metastatic cells, we examined the sensitivity of lineage-related human bladder cancer cell lines with different lung colonization abilities to chloroquine (CQ) or bafilomycin A₁, which are inhibitors of lysosome function and autophagy. Both CQ and bafilomycin A₁ were more cytotoxic in vitro to highly metastatic cells compared with their less metastatic counterparts. Genetic inactivation of macroautophagy regulators and lysosomal proteins indicated that this was due to greater reliance on the lysosome but not upon macroautophagy. To identify the mechanism underlying these effects, we generated cells resistant to CQ in vitro. Surprisingly, selection for in vitro CQ resistance was sufficient to alter gene expression patterns such that unsupervised cluster analysis of whole-transcriptome data indicated that selection for CQ resistance alone created tumor cells that were more similar to the poorly metastatic parental cells from which the metastatic cells were derived; importantly, these tumor cells also had diminished metastatic ability in vivo. These effects were mediated in part by differential expression of the transcriptional regulator ID4 (inhibitor of DNA binding 4); depletion of ID4 both promoted in vitro CQ sensitivity and restored lung colonization and metastasis of CQ-resistant cells. These data demonstrate that selection for metastasis ability confers selective vulnerability to lysosomal inhibitors and identify ID4 as a potential biomarker for the use of lysosomal inhibitors to reduce metastasis in patients.

DOI: 10.1073/pnas.1706526115
PubMed: 30127018

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000091
to stream PubMed, to step Curation: 000091
to stream PubMed, to step Checkpoint: 000097

Links to Exploration step

pubmed:30127018

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Metastatic cells are preferentially vulnerable to lysosomal inhibition.</title>
<author><name sortKey="Morgan, Michael J" sort="Morgan, Michael J" uniqKey="Morgan M" first="Michael J" last="Morgan">Michael J. Morgan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045; morgan83@nsuok.edu dan.theodorescu@cshs.org.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:regionArea>
<wicri:noRegion>Aurora</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fitzwalter, Brent E" sort="Fitzwalter, Brent E" uniqKey="Fitzwalter B" first="Brent E" last="Fitzwalter">Brent E. Fitzwalter</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Owens, Charles R" sort="Owens, Charles R" uniqKey="Owens C" first="Charles R" last="Owens">Charles R. Owens</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>University of Colorado Comprehensive Cancer Center, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Powers, Rani K" sort="Powers, Rani K" uniqKey="Powers R" first="Rani K" last="Powers">Rani K. Powers</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Sottnik, Joseph L" sort="Sottnik, Joseph L" uniqKey="Sottnik J" first="Joseph L" last="Sottnik">Joseph L. Sottnik</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>University of Colorado Comprehensive Cancer Center, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gamez, Graciela" sort="Gamez, Graciela" uniqKey="Gamez G" first="Graciela" last="Gamez">Graciela Gamez</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Costello, James C" sort="Costello, James C" uniqKey="Costello J" first="James C" last="Costello">James C. Costello</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Theodorescu, Dan" sort="Theodorescu, Dan" uniqKey="Theodorescu D" first="Dan" last="Theodorescu">Dan Theodorescu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045; morgan83@nsuok.edu dan.theodorescu@cshs.org.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:regionArea>
<wicri:noRegion>Aurora</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thorburn, Andrew" sort="Thorburn, Andrew" uniqKey="Thorburn A" first="Andrew" last="Thorburn">Andrew Thorburn</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30127018</idno>
<idno type="pmid">30127018</idno>
<idno type="doi">10.1073/pnas.1706526115</idno>
<idno type="wicri:Area/PubMed/Corpus">000091</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000091</idno>
<idno type="wicri:Area/PubMed/Curation">000091</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000091</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000097</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000097</idno>
<idno type="wicri:Area/Ncbi/Merge">000463</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Metastatic cells are preferentially vulnerable to lysosomal inhibition.</title>
<author><name sortKey="Morgan, Michael J" sort="Morgan, Michael J" uniqKey="Morgan M" first="Michael J" last="Morgan">Michael J. Morgan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045; morgan83@nsuok.edu dan.theodorescu@cshs.org.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:regionArea>
<wicri:noRegion>Aurora</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fitzwalter, Brent E" sort="Fitzwalter, Brent E" uniqKey="Fitzwalter B" first="Brent E" last="Fitzwalter">Brent E. Fitzwalter</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Owens, Charles R" sort="Owens, Charles R" uniqKey="Owens C" first="Charles R" last="Owens">Charles R. Owens</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>University of Colorado Comprehensive Cancer Center, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Powers, Rani K" sort="Powers, Rani K" uniqKey="Powers R" first="Rani K" last="Powers">Rani K. Powers</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Sottnik, Joseph L" sort="Sottnik, Joseph L" uniqKey="Sottnik J" first="Joseph L" last="Sottnik">Joseph L. Sottnik</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>University of Colorado Comprehensive Cancer Center, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gamez, Graciela" sort="Gamez, Graciela" uniqKey="Gamez G" first="Graciela" last="Gamez">Graciela Gamez</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Costello, James C" sort="Costello, James C" uniqKey="Costello J" first="James C" last="Costello">James C. Costello</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Theodorescu, Dan" sort="Theodorescu, Dan" uniqKey="Theodorescu D" first="Dan" last="Theodorescu">Dan Theodorescu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045; morgan83@nsuok.edu dan.theodorescu@cshs.org.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:regionArea>
<wicri:noRegion>Aurora</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Thorburn, Andrew" sort="Thorburn, Andrew" uniqKey="Thorburn A" first="Andrew" last="Thorburn">Andrew Thorburn</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Colorado</region>
</placeName>
<wicri:cityArea>Department of Pharmacology, University of Colorado School of Medicine, Aurora</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="eISSN">1091-6490</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Chloroquine (pharmacology)</term>
<term>Drug Resistance, Neoplasm (drug effects)</term>
<term>Gene Expression Regulation, Neoplastic (drug effects)</term>
<term>Humans</term>
<term>Inhibitor of Differentiation Proteins (biosynthesis)</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (metabolism)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Lung Neoplasms (secondary)</term>
<term>Lysosomes (metabolism)</term>
<term>Lysosomes (pathology)</term>
<term>Macrolides (pharmacology)</term>
<term>Mice</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Proteins (biosynthesis)</term>
<term>Urinary Bladder Neoplasms (drug therapy)</term>
<term>Urinary Bladder Neoplasms (genetics)</term>
<term>Urinary Bladder Neoplasms (metabolism)</term>
<term>Urinary Bladder Neoplasms (pathology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Chloroquine (pharmacologie)</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Lysosomes (anatomopathologie)</term>
<term>Lysosomes (métabolisme)</term>
<term>Macrolides (pharmacologie)</term>
<term>Métastase tumorale</term>
<term>Protéines d'inhibition de la différenciation (biosynthèse)</term>
<term>Protéines tumorales (biosynthèse)</term>
<term>Régulation de l'expression des gènes tumoraux ()</term>
<term>Résistance aux médicaments antinéoplasiques ()</term>
<term>Souris</term>
<term>Tumeurs de la vessie urinaire (anatomopathologie)</term>
<term>Tumeurs de la vessie urinaire (génétique)</term>
<term>Tumeurs de la vessie urinaire (métabolisme)</term>
<term>Tumeurs de la vessie urinaire (traitement médicamenteux)</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (métabolisme)</term>
<term>Tumeurs du poumon (secondaire)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Inhibitor of Differentiation Proteins</term>
<term>Neoplasm Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Chloroquine</term>
<term>Macrolides</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Lysosomes</term>
<term>Tumeurs de la vessie urinaire</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Protéines d'inhibition de la différenciation</term>
<term>Protéines tumorales</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term>
<term>Gene Expression Regulation, Neoplastic</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term>
<term>Urinary Bladder Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Urinary Bladder Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Tumeurs de la vessie urinaire</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung Neoplasms</term>
<term>Lysosomes</term>
<term>Urinary Bladder Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Lysosomes</term>
<term>Tumeurs de la vessie urinaire</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term>
<term>Lysosomes</term>
<term>Urinary Bladder Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Chloroquine</term>
<term>Macrolides</term>
</keywords>
<keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de la vessie urinaire</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Mice</term>
<term>Neoplasm Metastasis</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Métastase tumorale</term>
<term>Régulation de l'expression des gènes tumoraux</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Molecular alterations that confer phenotypic advantages to tumors can also expose specific therapeutic vulnerabilities. To search for potential treatments that would selectively affect metastatic cells, we examined the sensitivity of lineage-related human bladder cancer cell lines with different lung colonization abilities to chloroquine (CQ) or bafilomycin A<sub>1</sub>
, which are inhibitors of lysosome function and autophagy. Both CQ and bafilomycin A<sub>1</sub>
 were more cytotoxic in vitro to highly metastatic cells compared with their less metastatic counterparts. Genetic inactivation of macroautophagy regulators and lysosomal proteins indicated that this was due to greater reliance on the lysosome but not upon macroautophagy. To identify the mechanism underlying these effects, we generated cells resistant to CQ in vitro. Surprisingly, selection for in vitro CQ resistance was sufficient to alter gene expression patterns such that unsupervised cluster analysis of whole-transcriptome data indicated that selection for CQ resistance alone created tumor cells that were more similar to the poorly metastatic parental cells from which the metastatic cells were derived; importantly, these tumor cells also had diminished metastatic ability in vivo. These effects were mediated in part by differential expression of the transcriptional regulator ID4 (inhibitor of DNA binding 4); depletion of ID4 both promoted in vitro CQ sensitivity and restored lung colonization and metastasis of CQ-resistant cells. These data demonstrate that selection for metastasis ability confers selective vulnerability to lysosomal inhibitors and identify ID4 as a potential biomarker for the use of lysosomal inhibitors to reduce metastasis in patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30127018</PMID>
<DateCompleted><Year>2018</Year>
<Month>10</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>10</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>115</Volume>
<Issue>36</Issue>
<PubDate><Year>2018</Year>
<Month>09</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Metastatic cells are preferentially vulnerable to lysosomal inhibition.</ArticleTitle>
<Pagination><MedlinePgn>E8479-E8488</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1706526115</ELocationID>
<Abstract><AbstractText>Molecular alterations that confer phenotypic advantages to tumors can also expose specific therapeutic vulnerabilities. To search for potential treatments that would selectively affect metastatic cells, we examined the sensitivity of lineage-related human bladder cancer cell lines with different lung colonization abilities to chloroquine (CQ) or bafilomycin A<sub>1</sub>
, which are inhibitors of lysosome function and autophagy. Both CQ and bafilomycin A<sub>1</sub>
 were more cytotoxic in vitro to highly metastatic cells compared with their less metastatic counterparts. Genetic inactivation of macroautophagy regulators and lysosomal proteins indicated that this was due to greater reliance on the lysosome but not upon macroautophagy. To identify the mechanism underlying these effects, we generated cells resistant to CQ in vitro. Surprisingly, selection for in vitro CQ resistance was sufficient to alter gene expression patterns such that unsupervised cluster analysis of whole-transcriptome data indicated that selection for CQ resistance alone created tumor cells that were more similar to the poorly metastatic parental cells from which the metastatic cells were derived; importantly, these tumor cells also had diminished metastatic ability in vivo. These effects were mediated in part by differential expression of the transcriptional regulator ID4 (inhibitor of DNA binding 4); depletion of ID4 both promoted in vitro CQ sensitivity and restored lung colonization and metastasis of CQ-resistant cells. These data demonstrate that selection for metastasis ability confers selective vulnerability to lysosomal inhibitors and identify ID4 as a potential biomarker for the use of lysosomal inhibitors to reduce metastasis in patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morgan</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045; morgan83@nsuok.edu dan.theodorescu@cshs.org.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fitzwalter</LastName>
<ForeName>Brent E</ForeName>
<Initials>BE</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Owens</LastName>
<ForeName>Charles R</ForeName>
<Initials>CR</Initials>
<AffiliationInfo><Affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Powers</LastName>
<ForeName>Rani K</ForeName>
<Initials>RK</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Computational Bioscience Program, University of Colorado School of Medicine, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sottnik</LastName>
<ForeName>Joseph L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo><Affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gamez</LastName>
<ForeName>Graciela</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Costello</LastName>
<ForeName>James C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Computational Bioscience Program, University of Colorado School of Medicine, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Theodorescu</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045; morgan83@nsuok.edu dan.theodorescu@cshs.org.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thorburn</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Colorado Comprehensive Cancer Center, Aurora, CO 80045.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 CA075115</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 CA150925</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 CA046934</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 CA143971</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 GM007635</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R29 CA075115</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 CA190170</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>08</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C490128">ID4 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D051796">Inhibitor of Differentiation Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>88899-55-2</RegistryNumber>
<NameOfSubstance UI="C040929">bafilomycin A1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2019 Apr;201(4):668-669</RefSource>
<PMID Version="1">30652990</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051796" MajorTopicYN="N">Inhibitor of Differentiation Proteins</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001749" MajorTopicYN="Y">Urinary Bladder Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ID4</Keyword>
<Keyword MajorTopicYN="Y">autophagy</Keyword>
<Keyword MajorTopicYN="Y">chloroquine</Keyword>
<Keyword MajorTopicYN="Y">lysosome</Keyword>
<Keyword MajorTopicYN="Y">metastasis</Keyword>
</KeywordList>
<CoiStatement>The authors declare no conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>8</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>10</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>8</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30127018</ArticleId>
<ArticleId IdType="pii">1706526115</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.1706526115</ArticleId>
<ArticleId IdType="pmc">PMC6130375</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>BMC Genomics. 2009 Jun 23;10:277</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19549304</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2008 Feb;4(2):151-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18188003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Cancer. 2008 May 30;8:154</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18513385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Mar 25;331(6024):1559-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21436443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 1973 May;11(3):765-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4133950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Bioinformatics. 2011 Aug 04;12:323</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21816040</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2009 Dec 25;625(1-3):220-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19836374</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):182-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26677873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2004 Nov 1;64(21):7813-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15520187</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1359-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2017;13(12):2056-2071</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28981387</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Cell Biol. 2010 Apr;22(2):241-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19945838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1415-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1403-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2011 Feb 15;17(4):654-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21325294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2012 May 22;109(21):8253-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22566612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioinformatics. 2004 Feb 12;20(3):307-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14960456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2013 Sep 9;24(3):379-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24029234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1369-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Signal. 2013 Apr 02;6(269):pl1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23550210</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2010 Jul 15;70(14):5649-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20610625</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1380-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2013 Apr 18;32(16):1995-2004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22777359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2005 Jul 7;24(29):4721-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15897910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014;10(11):2087-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25484088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Oct 1;10(10):1814-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25136801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genome Biol. 2011;12(4):R41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21527027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Cell Biol. 2012 Aug;22(8):407-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22748206</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2014 May 1;74(9):2579-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24590058</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2017 Sep;17(9):528-542</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28751651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2017 Mar 23;36(12):1619-1630</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27593926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Chromosomes Cancer. 2000 Mar;27(3):252-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10679914</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2017 Feb 17;429(4):515-530</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27932295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Discov. 2017 Nov;7(11):1266-1283</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28899863</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Discov. 2012 May;2(5):401-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22588877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Biol Cell. 2008 Nov;19(11):4651-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18768752</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Cell Biol. 2016 Apr;39:69-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26921697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 2009 Feb;174(2):371-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19147813</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2006 Jun;6(6):449-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16723991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2012 Feb 1;8(2):200-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22252008</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Enzymol. 2008;439:219-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18374168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2014 Aug;10(8):1391-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 2016;899:121-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27325265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6669-E6678</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27791036</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Clin Pract Oncol. 2008 Apr;5(4):206-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18253104</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EBioMedicine. 2016 Dec;14:15-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28029600</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2012 Jul 15;72(14):3499-511</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22802077</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biostatistics. 2003 Apr;4(2):249-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12925520</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Colorado</li>
</region>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Morgan, Michael J" sort="Morgan, Michael J" uniqKey="Morgan M" first="Michael J" last="Morgan">Michael J. Morgan</name>
</noRegion>
<name sortKey="Costello, James C" sort="Costello, James C" uniqKey="Costello J" first="James C" last="Costello">James C. Costello</name>
<name sortKey="Fitzwalter, Brent E" sort="Fitzwalter, Brent E" uniqKey="Fitzwalter B" first="Brent E" last="Fitzwalter">Brent E. Fitzwalter</name>
<name sortKey="Gamez, Graciela" sort="Gamez, Graciela" uniqKey="Gamez G" first="Graciela" last="Gamez">Graciela Gamez</name>
<name sortKey="Owens, Charles R" sort="Owens, Charles R" uniqKey="Owens C" first="Charles R" last="Owens">Charles R. Owens</name>
<name sortKey="Powers, Rani K" sort="Powers, Rani K" uniqKey="Powers R" first="Rani K" last="Powers">Rani K. Powers</name>
<name sortKey="Sottnik, Joseph L" sort="Sottnik, Joseph L" uniqKey="Sottnik J" first="Joseph L" last="Sottnik">Joseph L. Sottnik</name>
<name sortKey="Theodorescu, Dan" sort="Theodorescu, Dan" uniqKey="Theodorescu D" first="Dan" last="Theodorescu">Dan Theodorescu</name>
<name sortKey="Thorburn, Andrew" sort="Thorburn, Andrew" uniqKey="Thorburn A" first="Andrew" last="Thorburn">Andrew Thorburn</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000463 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000463 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:30127018
   |texte=   Metastatic cells are preferentially vulnerable to lysosomal inhibition.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:30127018" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Metastatic cells are preferentially vulnerable to lysosomal inhibition.

Metastatic cells are preferentially vulnerable to lysosomal inhibition.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki